Validation of dried blood samples for adalimumab in IBD-patients

Completed

• Conditions: Inflammatory Bowel Disease; 10017969

• Registration Number: NL-OMON46650
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 75

Inclusion Criteria

Age from 18 years, either male of female
Diagnosis of IBD
Receiving adalimumab therapy

Exclusion Criteria

Contra-indication to adalimumab (TBC, severe infections or congestive heart failure)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary: to investigate feasibility of DBS from finger prick for measuring<br /><br>adalimumab drug levels and antibodies-to-adalimumab compared with the results<br /><br>of venepuncture serum sample measurements.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>To compare levels of albumin and CRP from DBS with the results of venepuncture<br /><br>serum sample measurement and to investigate feasibility of DBS from finger<br /><br>prick at home.</p><br>